SAFE Agreement
Simple Agreement for Future Equity

Reference: SAFE-2026-003 Effective Date: 15 February 2026 Governing Law: England and Wales Classification: Confidential

Parties
Company
Helix Biotech Ltd
72 Science Park Road, Cambridge, CB4 0DW, United Kingdom
Investor
Beacon Ventures Fund II LP
8 St James's Square, London, SW1Y 4JU, United Kingdom
Key Financial Terms
Purchase Amount: £500,000 Valuation Cap: £8,000,000 post-money Discount Rate: 20%
Agreement
Signatures
For the Company
Signature
Name / Title: Dr. Amelia Hargreaves, CEO
Date: 15 February 2026
For the Investor
Signature
Name / Title: Thomas Beacon, General Partner
Date: 15 February 2026